KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables: 2009-2024

Historic Receivables for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $6.2 billion.

  • Regeneron Pharmaceuticals' Receivables fell 6.88% to $5.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 billion, marking a year-over-year increase of 1.57%. This contributed to the annual value of $6.2 billion for FY2024, which is 9.61% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Receivables stood at $6.2 billion for FY2024, which was up 9.61% from $5.7 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Receivables' 5-year high stood at $6.2 billion during FY2024, with a 5-year trough of $4.1 billion in FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Receivables averaged around $5.7 billion, with its median value being $5.7 billion (2023).
  • In the last 5 years, Regeneron Pharmaceuticals' Receivables spiked by 74.31% in 2020 and then declined by 11.73% in 2022.
  • Regeneron Pharmaceuticals' Receivables (Yearly) stood at $4.1 billion in 2020, then spiked by 46.71% to $6.0 billion in 2021, then dropped by 11.73% to $5.3 billion in 2022, then climbed by 6.35% to $5.7 billion in 2023, then grew by 9.61% to $6.2 billion in 2024.